Introduction: Lifestyle-based interventions that promote nutritional ketosis can be effective for T2D management. This three-month trial compared use of CGM or BGM to support a MSKDP delivered via continuous remote care.

Methods: In this randomized trial, CGM (N=81) or BGM (N=82) data were used by participants and the care team to support dietary adherence and medication management decisions. Differences in 90-day mean blood beta-hydroxybutyrate (BHB) levels and in changes in dietary intake and weight from baseline to three months (Base to M3) were assessed. This is a secondary and exploratory outcome analysis.

Results: Participants in CGM and BGM arms were not different at baseline (Mean + SD): 53 + 10 years old; 10 + 8 years with T2D; HbA1c 8.1% + 1.2%; taking 2.2 + 1.0 diabetes medications. The 90-day mean BHB levels were 0.54 mmol/L for CGM and 0.48 mmol/L for BGM; p=0.24. Energy and carbohydrate intake decreased significantly (Base to M3), with no differences between arms. Weight change did not differ between arms. See Table 1. Mean 90-day BHB levels were negatively correlated with carbohydrate intake (r= -0.26; p=0.02) and weight change (r= -0.28; p=0.01) at M3.

Conclusion: The MSKDP led to large decreases in energy and carbohydrate intake, and both CGM and BGM led to similar BHB levels and weight change.


H.J. Willis: Research Support; Abbott. Other Relationship; Abbott. Research Support; Academy of Nutrition and Dietetics, Dexcom, Inc. A.L. McKenzie: Employee; Virta Health Corp. Stock/Shareholder; Virta Health Corp. Employee; Abbott. C.G.P. Roberts: Other Relationship; Virta Health Corp. S.E. Asche: Stock/Shareholder; Gilead Sciences, Inc., AbbVie Inc., GlaxoSmithKline plc. S. Krizka: None. R.N. Adams: Employee; Virta Health Corp. Stock/Shareholder; Virta Health Corp. B.M. Volk: Employee; Virta Health Corp. Stock/Shareholder; Virta Health Corp. A.R. Zoller: Employee; Virta Health Corp. Stock/Shareholder; Virta Health Corp. S.J. Athinarayanan: Employee; Virta Health Corp. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S.


Abbott Diabetes Care

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at